As a tribute to Dr. Jack Mendelson's remarkable contributions to the field of clinical alcohol research, the National Institute on Alcohol Abuse and Alcoholism established this honorary lecture series. Each year, the series features a lecture by an outstanding alcohol investigator whose clinical research makes a substantial contribution to our understanding of: Susceptibility to alcohol use disorder Alcohol's effects on...
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Extramural Research The NIAAA extramural research portfolio is wide-ranging and varied. NIAAA determines its research priorities through guidance from: National Advisory Council and its subcommittees Input from researchers in the field Input from NIAAA research staff Input from liaison groups Important themes at national and international meetings and conferences NIAAA Strategic Plan NIAAA Health Disparities Strategic Plan Congressional legislation and...
Research on Promising Medications (not approved by the U.S. Food and Drug Administration [FDA]) to Treat Alcohol Use Disorder (AUD) Varenicline (Chantix®), a medication approved for smoking cessation, was found in a recent 200-patient clinical trial conducted by NIAAA’s Clinical Investigations Group (NCIG) to reduce alcohol consumption and craving among people who are alcohol-dependent. Varenicline may work by partially stimulating...
Understanding Fetal Alcohol Spectrum Disorders (FASD): Promising Practices for System Involved Youth with FASD FASD is a group of medical conditions that describe a range of effects that can occur in an individual prenatally exposed to alcohol. These effects, often invisible, may include mental, behavioral, and or learning disabilities with lifelong implications. This session will highlight available resources on this...